Literature DB >> 19654152

Aprotinin protects the cerebral microcirculation during cardiopulmonary bypass.

N Ishibashi1, Y Iwata, D Zurakowski, H G W Lidov, R A Jonas.   

Abstract

BACKGROUND AND
OBJECTIVE: We have previously reported that administration of aprotinin at a single dose protects the cerebral microcirculation. The current study was designed to identify the optimal dose for protecting the cerebral microcirculation with assessment of neurological and behavioral recovery as well as renal function after circulatory arrest and ultra-low-flow bypass.
METHODS: Twenty-four piglets were randomly assigned to three bypass groups at risk for postoperative cerebral and renal dysfunction. Cerebral microcirculation was assessed by intravital microscopy. Rhodamine-stained leukocytes were observed for adhesion and rolling. Animals were randomized to one of four aprotinin doses. Neurological deficit score, histological score, creatinine and blood urea nitrogen were analyzed, both independently for this study as well as in combination with 50 animals who were studied with the same protocol and near-infrared spectroscopy.
RESULTS: There was a dose-dependent relationship, resulting in fewer activated rolling leukocytes with a higher aprotinin dose. Aprotinin dose was an independent predictor of more rapid recovery of neurological and behavioral outcome. We present a linear regression model where aprotinin dose predicts neurological score. Aprotinin had no impact on renal function.
CONCLUSIONS: Aprotinin reduces cerebral leukocyte activation and accelerates neurologic recovery in a dose-dependent fashion. Aprotinin has no measurable impact on standard indices of renal function in young piglets. The current lack of availability of aprotinin is a serious disadvantage for pediatric patients undergoing cardiopulmonary bypass.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19654152      PMCID: PMC2853023          DOI: 10.1177/0267659109106701

Source DB:  PubMed          Journal:  Perfusion        ISSN: 0267-6591            Impact factor:   1.972


  24 in total

1.  An anti-inflammatory property of aprotinin detected at the level of leukocyte extravasation.

Authors:  G Asimakopoulos; R Thompson; S Nourshargh; E A Lidington; J C Mason; C P Ratnatunga; D O Haskard; K M Taylor; R C Landis
Journal:  J Thorac Cardiovasc Surg       Date:  2000-08       Impact factor: 5.209

2.  Effects of pH management during deep hypothermic bypass on cerebral microcirculation: alpha-stat versus pH-stat.

Authors:  Lennart F Duebener; Ikuo Hagino; Takahiko Sakamoto; Lotfi Ben Mime; Christof Stamm; David Zurakowski; Hans-Joachim Schäfers; Richard A Jonas
Journal:  Circulation       Date:  2002-09-24       Impact factor: 29.690

3.  Effects of aprotinin on acute recovery of cerebral metabolism in piglets after hypothermic circulatory arrest.

Authors:  M Aoki; R A Jonas; F Nomura; M E Stromski; M K Tsuji; P R Hickey; D H Holtzman
Journal:  Ann Thorac Surg       Date:  1994-07       Impact factor: 4.330

4.  Effect of aprotinin on need for blood transfusion after repeat open-heart surgery.

Authors:  D Royston; B P Bidstrup; K M Taylor; R N Sapsford
Journal:  Lancet       Date:  1987-12-05       Impact factor: 79.321

5.  The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling.

Authors:  O Nicole; F Docagne; C Ali; I Margaill; P Carmeliet; E T MacKenzie; D Vivien; A Buisson
Journal:  Nat Med       Date:  2001-01       Impact factor: 53.440

Review 6.  The antithrombotic and antiinflammatory mechanisms of action of aprotinin.

Authors:  R C Landis; G Asimakopoulos; M Poullis; D O Haskard; K M Taylor
Journal:  Ann Thorac Surg       Date:  2001-12       Impact factor: 4.330

7.  Higher hematocrit improves cerebral outcome after deep hypothermic circulatory arrest.

Authors:  T Shin'oka; D Shum-Tim; R A Jonas; H G Lidov; P C Laussen; T Miura; A du Plessis
Journal:  J Thorac Cardiovasc Surg       Date:  1996-12       Impact factor: 5.209

8.  Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion.

Authors:  Y T Wachtfogel; U Kucich; C E Hack; P Gluszko; S Niewiarowski; R W Colman; L H Edmunds
Journal:  J Thorac Cardiovasc Surg       Date:  1993-07       Impact factor: 5.209

9.  University of Wisconsin cerebroplegia in a piglet survival model of circulatory arrest.

Authors:  J M Forbess; J C Ibla; H G Lidov; M A Cioffi; T Hiramatsu; P Laussen; T Miura; R A Jonas
Journal:  Ann Thorac Surg       Date:  1995-12       Impact factor: 4.330

10.  Optimal dose of aprotinin for neuroprotection and renal function in a piglet survival model.

Authors:  Yusuke Iwata; Toru Okamura; Nobuyuki Ishibashi; David Zurakowski; Hart G W Lidov; Richard A Jonas
Journal:  J Thorac Cardiovasc Surg       Date:  2009-04-21       Impact factor: 5.209

View more
  3 in total

1.  Differential effects of aprotinin and tranexamic acid on outcomes and cytokine profiles in neonates undergoing cardiac surgery.

Authors:  Eric M Graham; Andrew M Atz; Jenna Gillis; Stacia M Desantis; A Lauren Haney; Rachael L Deardorff; Walter E Uber; Scott T Reeves; Francis X McGowan; Scott M Bradley; Francis G Spinale
Journal:  J Thorac Cardiovasc Surg       Date:  2011-11-09       Impact factor: 5.209

2.  Differential neuronal vulnerability varies according to specific cardiopulmonary bypass insult in a porcine survival model.

Authors:  Nobuyuki Ishibashi; Yusuke Iwata; Toru Okamura; David Zurakowski; Hart G W Lidov; Richard A Jonas
Journal:  J Thorac Cardiovasc Surg       Date:  2010-12       Impact factor: 5.209

3.  Aprotinin, but not ε-aminocaproic acid and tranexamic acid, exerts neuroprotection against excitotoxic injury in an in vitro neuronal cell culture model.

Authors:  Zhaohui Lu; Ludmila Korotcova; Akira Murata; Nobuyuki Ishibashi; Richard A Jonas
Journal:  J Thorac Cardiovasc Surg       Date:  2013-11-13       Impact factor: 5.209

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.